Global data science and digital health company Holmusk has bought UK-based mental health predictive analytics provider Otsuka Health Solutions (OHS).
Holmusk says the acquisition from Otsuka Pharmaceutical Europe will deepen its footprint in the UK and lead to expaning its partnerships with health systems working to transform behavioural healthcare.
The acquisition also sees Holmusk add OHS’s Management and Supervision Tool (MaST) to its suite of digital and analytic solutions to improve behavioural health outcomes.
The MaST digital platform for care teams, uses predictive analytics to identify people at greater risk of using crisis services and those who may require different services to support their recovery with the aim of ensuring fewer people in crisis require inpatient admissions when compared with standard community management.
Commenting on the acquisition, Holmusk founder and CEO Nawal Roy said: “This acquisition is an important milestone in our ambition to lead behavioural health innovation globally.
“The UK has long held a reputation as a centre of excellence for mental health research, and we are excited to bolster our presence here, leveraging OHS’s current role as a key partner with NHS Trusts, mental health research institutions, and providers.”
Caroline Gadd, former director of OHS and now director of healthcare solutions at Holmusk said the team was delighted to join Holmusk.
“Holmusk’s capabilities and experience in measuring patient-reported outcomes will accelerate MaST’s development, allowing us to strive towards continually improving mental health outcomes as new models of care emerge across the NHS.”